Shandong Fangming Pharmaceutical

Shandong Fangming Pharmaceutical Group is a comprehensive pharmaceutical company headquartered in Heze, Shandong Province, China. Founded in 1972, the company has evolved into a major manufacturer of active pharmaceutical ingredients (APIs) and finished dosage forms, including tablets, capsules, and both small and large-volume injections. Its product portfolio is primarily focused on therapeutic areas such as analgesia, cardiovascular disease, and anti-infectives, featuring well-known generic products like Metamizole Sodium. In 2009, the company was acquired by Fosun Pharma, becoming a key part of its pharmaceutical manufacturing and supply chain strategy. Shandong Fangming operates several GMP-certified facilities and maintains a strong presence in both the Chinese domestic market and international export markets. The company is recognized as one of the largest production bases for Metamizole Sodium in the country.